LEGN vs. BNTX, TEVA, INSM, SMMT, ITCI, GMAB, RDY, QGEN, MRNA, and ASND
Should you be buying Legend Biotech stock or one of its competitors? The main competitors of Legend Biotech include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.
Legend Biotech vs. Its Competitors
BioNTech (NASDAQ:BNTX) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.
BioNTech currently has a consensus target price of $137.86, indicating a potential upside of 25.73%. Legend Biotech has a consensus target price of $72.60, indicating a potential upside of 105.37%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than BioNTech.
Legend Biotech has lower revenue, but higher earnings than BioNTech. Legend Biotech is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.
BioNTech has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500.
BioNTech has a net margin of -27.37% compared to Legend Biotech's net margin of -29.95%. BioNTech's return on equity of -3.94% beat Legend Biotech's return on equity.
In the previous week, Legend Biotech had 5 more articles in the media than BioNTech. MarketBeat recorded 8 mentions for Legend Biotech and 3 mentions for BioNTech. Legend Biotech's average media sentiment score of 0.64 beat BioNTech's score of 0.07 indicating that Legend Biotech is being referred to more favorably in the news media.
15.5% of BioNTech shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
BioNTech beats Legend Biotech on 9 of the 17 factors compared between the two stocks.
Get Legend Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Legend Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:LEGN) was last updated on 7/6/2025 by MarketBeat.com Staff
Free LEGN Stock Alerts